MEI Pharma

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an investigational phosphatidylin

MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2022, and highlighted recent corporate events. “The third fiscal quarter of 2022 was underscored by a meeting with the FDA in which we were informed that data from randomized studies are now needed to adequately assess the benefit-risk of PI3K inhibitor drug candidates, including zandelisib, and whe

MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights

Los Angeles, California--(Newsfile Corp. - May 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. MEI Pharma announced restatements of certain quarterly financial statements from...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. (“MEI” or the “Company”) (NASDAQ: MEIP) on behalf of MEI stockholders. Our investigation concerns whether MEI has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 13, 2022, after market hours, MEI Pharma announced restatements of its fina

MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm

Los Angeles, California--(Newsfile Corp. - May 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. MEI Pharma announced restatements of certain quarterly financial statements from...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm

MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your MEI Pharma investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) investors concerning the Company's possible violations of federal securities laws. On May 13, 2022, after the market closed, MEI Pharma announced that it would restate certain financial results because "revenue was overstated in some quarters and understated in other quarters in the Company's financial statements during 2020 and 2

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022. The company will present a company overview and business update available for on-demand listening starting Tuesday, May 24, 2022, 7:00 a.m. Eastern Time that will be archived for 90 days. The presentation can be accessed via the Events & Presentations page of

MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 13, 2022, after the market closed, MEI Pharma announced that it would restate certain financial results because "revenue was overstated in some quarters and understat

The Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MEI Pharma, Inc. (NASDAQ: MEIP) resulting from allegations that MEI Pharma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased MEI Pharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme

Rosen Law Firm Encourages MEI Pharma, Inc. Investors with Losses to Inquire About Class Action Investigation – MEIP

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that two abstracts highlighting data and information for zandelisib, an investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor in clinical develop

MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress

Evoke Pharma

Globalstar

IT Tech Packaging Inc

Kala Pharmaceuticals

Kiromic Biopharma

Pingtan Marine Enterprise

PolarityTE Inc

Sesen Bio Inc.

Sonim Technologies Inc

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two posters presenting preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 for zandelisib, an orally administered phosphatidylinositol-3-kinase (PI3K) inhibitor, and ME-344, a tumor selective mitochondrial inhibitor. “The preclinical data presented at AACR is supportive of th

MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022

Vinco Ventures

Camber Energy

Clever Leaves Holdings Inc

SNDL Inc.

Penny stocks with interesting options activity today. The post 5 Penny Stocks To Buy According To Big Money Options Bets Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy According To Big Money Options Bets Right Now

Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.

Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug

The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the meeting, the FDA informed that a randomized clinical trial is "needed to adequately assess drug efficacy and safety.

Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

Honest Co

We're checking in on the latest penny stocks news for today with two companies that investors are watching fall on Friday! The post Penny Stocks Today: Why MEIP and HNST Are Plunging Friday appeared first on InvestorPlace.

Penny Stocks Today: Why MEIP and HNST Are Plunging Friday

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration. During the meeting, the FDA informed MEI Pharma that a randomized trial would .

Why MEI Pharma Stock Is Plummeting After Hours

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administration (FDA) to discuss the pursuit of a marketing authorization for zandelisib, a phosphatidylinositol-3-kinase (“PI3K”) inhibitor drug candidate, via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study. In the meetin

MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Research Annual Meeting 2022 to be held April 8 – 13, 2022. Details of the poster presentations: Title: Efficacy and immune profiling of the PI3K delta inhibitor zandelisib (ME-401) in a

MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2021, and highlighted recent corporate progress. “The next few quarters have the makings for a potentially transformational period for MEI Pharma, headlined by complete Phase 2 TIDAL data in follicular lymphoma later in the year, which we believe will provide the foundation to support our plan to

MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with the addition of two experienced industry executives. Alejandro Ricart, M.D., joins MEI as senior vice president, clinical development, a role that will report to Richard Ghalie, M.D., chief medical officer, and Yomara Gomez-Naiden joins as senior vice president, quality, reporting to Daniel P. Go

News for MEI Pharma Stock (MEIP)